Macrophages in Lung Cancer and Patient Survival
Author Information
Author(s): Kim D-W, Min H S, Lee K-H, Kim Y J, Oh D-Y, Jeon Y K, Lee S-H, Im S-A, Chung D H, Kim Y T, Kim T-Y, Bang Y-J, Sung S W, Kim J H, Heo D S
Primary Institution: Seoul National University Hospital
Hypothesis
The study investigates the prognostic value of tumour-associated macrophages and their relationship with EGFR mutations in non-small cell lung cancer (NSCLC).
Conclusion
High tumour islet macrophage infiltration is a strong independent prognostic marker for improved survival in patients with resected NSCLC.
Supporting Evidence
- Patients with high tumour islet macrophage density had a 5-year overall survival rate of 63.9%.
- The study included 144 patients who underwent surgery for NSCLC.
- EGFR mutations were found in 20.1% of patients, but these were not related to macrophage infiltration.
Takeaway
This study found that having more macrophages in the tumor islet area can help patients with lung cancer live longer, but it doesn't relate to certain gene changes.
Methodology
The study used immunohistochemistry to identify CD68+ macrophages and analyzed EGFR mutations through direct sequencing in patients who underwent surgery for NSCLC.
Limitations
The study did not find a correlation between EGFR mutations and macrophage infiltration, which may limit the understanding of macrophage behavior in relation to molecular changes.
Participant Demographics
The mean age of participants was 60.4 years, with 74% male and various stages of NSCLC represented.
Statistical Information
P-Value
0.0002
Confidence Interval
0.300–0.740
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website